Clinical Trial Update: A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating weekly epoetin alfa at two doses versus placebo in patients with low or intermediate-1 risk myelodysplastic syndromes at risk for tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Myelodysplastic Syndromes, Anemia | Phase 3 | Status: TERMINATED | Results posted: 2011-03-17